Capricor Therapeutics Investors Can Lead Shareholder Class Action
Investors who purchased Capricor Therapeutics, Inc. (NASDAQ: CAPR) securities between December 17, 2025, and July 26, 2026, have until September 28, 2026, to seek lead plaintiff status in a shareholder class action lawsuit.
Investors who acquired shares of Capricor Therapeutics, Inc. (NASDAQ: CAPR) during a specified period may be eligible to recover losses. The deadline to participate in the potential class action lawsuit is September 28, 2026.
The law firm Robbins Geller Rudman & Dowd LLP announced that purchasers of Capricor Therapeutics securities between December 17, 2025, and July 26, 2026, inclusive, have the opportunity to serve as lead plaintiff.
This legal action stems from allegations that Capricor Therapeutics made materially misleading statements or omissions during the class period. Such claims typically involve inaccuracies in public statements or failure to disclose critical information that could affect stock valuation.
Shareholders who experienced substantial losses and wish to pursue a claim or potentially lead the class action should contact Robbins Geller Rudman & Dowd LLP before the September 28 deadline. The specific details of the alleged misconduct have not yet been fully elaborated by the filing firm.